deltatrials
Unknown PHASE3 NCT04400695

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Sponsor: RemeGen Co., Ltd.

Conditions Breast Cancer
Interventions Capecitabine Tablets Docetaxel Injection Paclitaxel Injection RC48-ADC Vinorelbine Tartrate Injection
Updated 10 times since 2020 Last updated: Jan 22, 2024 Started: Sep 29, 2020 Primary completion: Jun 30, 2024 Completion: Dec 30, 2024

A PHASE3 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by RemeGen Co., Ltd. and has accumulated 10 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

10 versions recorded

  1. Jan 2026 — Present [monthly]

    Unknown PHASE3

    Status: Recruiting → Unknown

  2. Sep 2024 — Jan 2026 [monthly]

    Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  4. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  5. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE3

▶ Show 5 earlier versions

  1. Dec 2021 — Jan 2024 [monthly]

    Recruiting PHASE3

  2. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  3. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  4. Jan 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE3

  5. Jun 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RemeGen Co., Ltd.
Data source: RemeGen Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Beijing, China